Overview

Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This is a review of the efficacy and safety of different recombinant human thrombopoietin (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP).
Phase:
Phase 4
Details
Lead Sponsor:
Shenyang Sunshine Pharmaceutical Co., LTD.